Key Dates

Related Announcements

PAR-22-139 - Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)

PAR-22-140 - Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The National Cancer Institute (NCI) will hold a public pre-application webinar on April 14, 2022, at 3:00 - 5:00 pm EDT.

NCI staff members involved in managing this program will assist potential applicants by explaining the goals and objectives of this initiative and answering questions from attendees. Prospective applicants are encouraged to submit their questions or comments to [email protected] in advance of the webinar.

Registration: Potential applicants interested in participating in the webinar should send an email to:

Ms. Julie Hong ([email protected]) to obtain registration information no later than 5:00 p.m. (EDT) April 07, 2022.

Please include "NCI Assistance Webinar for STRIPE RFA” in the subject line of the email.

Participation in this webinar, although encouraged, is optional and is not required for the submission of an application in response to PAR-22-139 and PAR-22-140.

Inquiries

Please direct all inquiries to:

Michael Graham Espey, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5690
Email: [email protected]

Jacek Capala, Ph.D.
National Cancer (NCI)
Telephone: 240-276-5690
Email: [email protected]